MYADM and pulmonary arterial hypertension: However, compared with the wild-type controls, Myadm-/- rats exhibited significantly lower baseline levels of Myadm in lung tissue homogenates (Figure 5A-B) and marked protection against the pathobiology of PAH; this was evidenced by lower RVSP and PASP, decreased RVSP (Figure 5C-D), increased TAPSE and PVmax (Figure S5A-B), less severe pulmonary vascular remodeling (Figure 5E-F) and remissive fibrosis of the myocardium in response to MCT (Figure S5C-E).